Treatment-resistant obesity/adiposity-based chronic disease (ABCD) affects approximately 20-30% of cases, presenting significant challenges beyond insulin resistance. This review proposes that SULT-mediated lipid sulfation, facilitated by enzymes SULT1A1, SULT1E1, and SULT2B1, drives this phenotype through activation of the LXR/SREBP-1c axis.
Key Clinical Findings
Upregulated SULTs catalyze PAPS-dependent sulfation of sterols and fatty acids, producing cholesterol sulfate which acts as an LXRα agonist. This process amplifies SREBP-1c expression, increasing the synthesis of FASN and ACACA, resulting in approximately 40% enhanced triglyceride production. Simultaneously, sulfated lipids stabilize perilipins, repelling ATGL and HSL to reduce non-esterified fatty acid release by approximately 50%. Mitochondrial integration impairs CPT1 and ETFDH, attenuating β-oxidation by approximately 30%. Endocrine perturbations, including T3/T4 sulfation, diminish DIO2 affinity and lower basal metabolic rate, synergizing with intact insulin signaling to maintain depot stability.
Novel Therapeutic Approaches
This differs from conventional ABCD, which involves reversible TAG cycling and IRS desensitization. Supporting evidence includes SULT1A1 knockouts conferring approximately 10-15% weight reduction and UCP1 elevation, SULT2B1 inhibition preventing high-fat diet-induced ABCD via enhanced energy expenditure, and human lipidomics showing elevated cholesterol sulfate correlating with BMI. MHO phenotypes, with preserved glucose tolerance despite high adiposity, highlight the novelty, as do high-starch diet models exhibiting ABCD without glucose intolerance. Plasma cholesterol sulfate emerges as a diagnostic biomarker for stratifying resistant cases. Novel sulfur-based interventions, including sulfatase activators, taurine, molybdenum, thiol antioxidants, and steroid desulfators, modulate lipid sulfation pathways to enhance β-oxidation, mobilize non-esterified fatty acids, suppress adipogenesis, and restore endocrine balance.